ABBV-453

A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

What's the purpose of the trial?

The purpose of this study is to assess the safety and toxicity of ABBV-453 in adult participants with relapsed/refractory (R/R) MM.

Trial status

Accepting patients

Phase
Phase 1
Enrollment
21
Last Updated
5 months ago
Am I Eligible

Participating Centers

There are 12 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • ABBV-453 is an investigational drug being developed for the treatment of relapsed/refractory multiple myeloma. It is a first-in-human, BCL-2 inhibitor.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

ABBV-453

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.